NVIDIA and Eli Lilly announced a $1 billion collaboration to build an AI-powered drug discovery laboratory in the San Francisco Bay Area. The multi-year partnership will combine NVIDIA’s compute and AI infrastructure with Lilly’s drug discovery and clinical expertise to accelerate biologics design, small‑molecule discovery and predictive models for clinical outcomes. Both parties said the lab aims to scale AI-first workflows across discovery and preclinical development.